Under the agreement, Defence will develop the first radio-immuno-conjugate therapy based on an Auger electron emitter by combining Defence’s intracellular targeting and radiochemistry expertise provided by Orano SA, a world-renowned multinational company based in Chatillon, France.
Read MoreAstraZeneca is pleased to announce it is bringing 500 highly-skilled scientific and high-tech jobs to the Greater Toronto Area (GTA) in a major expansion of its research footprint in Canada. The investment will contribute to AstraZeneca’s Research & Development Hub (R&D) in Mississauga, which focuses on leading global clinical studies in areas including breast, lung and prostate cancer, COVID-19, and chronic kidney disease. It also includes the creation of a new Alexion, AstraZeneca Rare Disease Development Hub, which focuses on rare disease research.
Read MoreToday, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, and the Honourable Jean-Yves Duclos, Minister of Health, announced an investment of $10 million in support of the creation of five research hubs to accelerate Canada’s vaccine and therapeutics production.
Read MoreCongruence Therapeutics, announced today the close of an extension to its Series A financing, bringing the total amount raised to over US$65 million. This extension was led by new investor BDC Capital's Thrive Venture Fund, with participation from current investors Amplitude Ventures, Fonds de solidarité FTQ, OrbiMed, Investissement Quebec (IQ), SilverArc, and others.
Read MoreWe would like to notify you that as of February 17, 2023, Emmanuelle Toussaint no longer holds the position of Executive Director at BIOQuébec. BIOQuébec is very appreciative of the tremendous work done by Emmanuelle and grateful for her dedication and involvement over the past six months. We wish her continued success in her professional journey.
Read MoreThe Governments of Canada and Prince Edward Island today announced funding for a $50 million BioAccelerator, which will be home to CASTL’s (Canadian Alliance for Skills and Training in Life Sciences) headquarters and expanded training facility.
Read MoreAplantex is pleased to announce the composition of the company’s C-suite. "Aplantex is the result of the innovative work of a multidisciplinary team of skilled individuals committed to simplifying and broadening access to the valuable plant-based bioactive molecules that daily impact our health and well-being," states Mr. Charest.
Read MoreDefence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the validation of its ARM vaccine candidate in a melanoma model with a cure rate of 60%.
Read MoreAmgen, one of the world’s leading biotechnology companies, and Mila – Quebec Artificial Intelligence Institute, are expanding their partnership aimed at further transforming Artificial Intelligence (AI) guided drug development. As part of this evolution, Amgen is establishing a corporate laboratory within Mila’s headquarters where scientists from both organizations will interact and engage.
Read MoreThe Honourable Pablo Rodriguez, Minister of Canadian Heritage and Quebec Lieutenant, today announced, on behalf of the Honourable Pascale St–Onge, Minister of Sport and Minister responsible for Canada Economic Development for Quebec Regions (CED), a repayable contribution of $600,000 for CIRION BioPharma Research Inc.
Read MoreThe Canadian Alliance for Skills and Training in Life Sciences (CASTL) announced its expansion into Quebec with the location of their future Biomanufacturing Training Facility in Montreal.
Read MoreGiiant Pharma Inc., a Canadian, preclinical-stage biotech company, today announced that the Company will receive financial support from the US Crohn’s and Colitis Foundation, through its IBD Ventures program, for an amount up to US$ 500,000.
Read MoreDomain Therapeutics, a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announces that the first patient has been dosed with DT-9081, Domain’s proprietary IO asset, in a first-in-human Phase I study.
Read MoreAbCellera announced today that it has entered into a multi-year, multi-target strategic collaboration with AbbVie Inc. The partnership will leverage AbCellera’s antibody discovery and development engine to deliver optimized development candidates for up to five targets selected by AbbVie across multiple indications.
Read MoreIMV Inc. today announced positive initial patient data from the VITALIZE Phase 2B trial evaluating its lead DPX product, MVP-S, in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma (“r/r DLBCL”) who received at least three previous lines of treatment.
Read MoreOn December 10th, 2021, BIOQuébec and other players in the life sciences industry in Quebec sent several federal elected officials their serious concerns regarding the coming into force of the PMPRB reform. As leading representatives of the Quebec life sciences sector who actively and strategically contribute to the country's economy, they asked that the implementation of the PMPRB reform be suspended. A year later, on December 5th, 2022, new developments compel Montréal InVivo, Sherbrooke Innopole and BIOQuébec to reiterate this request. A new request for the postponement of the coming into force of new guidelines has therefore been formulated as part of the PMPRB's consultation process.
Read MoreDefence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the successful completion of all GLP studies related to its anti-cancer treatment, AccuTOX.
Read MoreDomain Therapeutics, a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announces the appointments of Professor Antoine Italiano and Professor John Stagg to its Scientific Advisory Board (SAB).
Read MoreMONTREAL (CANADA) – November 29, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD).
Read More
